{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000074","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.678539+00:00","generated_at":"2026-05-17T18:59:13.014462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M","bullets":["Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.","Cash and securities $663.8M (Dec 2024: $706.7M); guidance for year-end $555-585M, runway into 2028.","Earned $25M regulatory milestone from Incyte for Monjuvi FDA approval in follicular lymphoma.","Initiated Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis; plans to present XmAb819 data in Q4 2025.","Appointed Raymond Deshaies, Ph.D., to board of directors; he previously led global research at Amgen."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000074","json":"https://secwatch.observer/filing/0001326732-25-000074.json","markdown":"https://secwatch.observer/filing/0001326732-25-000074.md","text":"https://secwatch.observer/filing/0001326732-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/0001326732-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/xncr-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:59:13.014462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}